Table 2 Number of participants reporting local and systemic solicited AEs.

From: A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial

 

ChAdOx1 Chik 5 × 109 vp (n = 6)

ChAdOx1 Chik 2.5 × 1010 vp (n = 9)

ChAdOx1 Chik 5 × 1010 vp (n = 9)

 

Any

Mild

Moderate

Severe

Any

Mild

Moderate

Severe

Any

Mild

Moderate

Severe

Any symptom

4 (67%)

4 (67%)

0

0

9 (100%)

6 (67%)

3 (33%)

0

9 (100%)

4 (44%)

3 (33%)

2 (22%)

Any local symptom

3 (50%)

3 (50%)

0

0

9 (100%)

8 (89%)

1 (11%)

0

7 (78%)

5 (56%)

2 (22%)

0

Pain

3 (50%)

3 (50%)

0

0

9 (100%)

8 (89%)

1 (11%)

0

7 (78%)

5 (56%)

2 (22%)

0

Pruritus

0

0

0

0

0

0

0

0

0

0

0

0

Warmth

0

0

0

0

4 (44%)

4 (44%)

0

0

3 (33%)

3 (33%)

0

0

Swelling

0

0

0

0

0

0

0

0

0

0

0

0

Erythema

0

0

0

0

0

0

0

0

1 (11%)

1 (11%)

0

0

Any systemic symptom

2 (33%)

2 (33%)

0

0

9 (100%)

6 (67%)

3 (33%)

0

9 (100%)

4 (44%)

3 (33%)

2 (22%)

Fever

0

0

0

0

2 (22%)

2 (22%)

0

0

2 (22%)

2 (22%)

0

0

Feverishness

1 (17%)

1 (17%)

0

0

6 (67%)

3 (33%)

3 (33%)

0

7 (78%)

4 (44%)

2 (22%)

1 (11%)

Arthralgia

0

0

0

0

3 (33%)

3 (33%)

0

0

4 (44%)

0

3 (33%)

1 (11%)

Myalgia

1 (17%)

1 (17%)

0

0

7 (78%)

6 (67%)

1 (11%)

0

6 (67%)

2 (22%)

3 (33%)

1 (11%)

Headache

1 (17%)

1 (17%)

0

0

7 (78%)

6 (67%)

1 (11%)

0

6 (67%)

3 (33%)

1 (11%)

2 (22%)

Fatigue

2 (33%)

2 (33%)

0

0

5 (56%)

5 (56%)

0

0

8 (89%)

4 (44%)

4 (44%)

0

Nausea

0

0

0

0

2 (22%)

1 (11%)

1 (11%)

0

3 (33%)

1 (11%)

2 (22%)

0

Malaise

1 (17%)

1 (17%)

0

0

6 (67%)

6 (67%)

0

0

5 (56%)

1 (11%)

3 (33%)

1 (11%)

Back to article page